Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/63820
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study |
Author: | Tebbutt, N. Wilson, K. Gebski, V. Cummins, M. Zannino, D. van Hazel, G. Robinson, B. Broad, A. Ganju, V. Ackland, S. Forgeson, G. Cunningham, D. Saunders, M. Stockler, M. Chua, Y. Zalcberg, J. Simes, R. Price, T. |
Citation: | Journal of Clinical Oncology, 2010; 28(19):3191-3198 |
Publisher: | Amer Soc Clinical Oncology |
Issue Date: | 2010 |
ISSN: | 0732-183X 1527-7755 |
Statement of Responsibility: | Niall C. Tebbutt, Kate Wilson, Val J. Gebski, Michelle M. Cummins, Diana Zannino, Guy A. van Hazel, Bridget Robinson, Adam Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark P. Saunders, Martin R. Stockler, YuJo Chua, John R. Zalcberg, R. John Simes and Timothy J. Price |
Abstract: | Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. Patients and Methods: Overall, 471 patients in Australia, New Zealand, and the United Kingdom with previously untreated, unresectable mCRC were randomly assigned to the following: capecitabine; capecitabine plus bevacizumab (CB); or capecitabine, bevacizumab, and mitomycin (CBM). We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL). Results: Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM (capecitabine v CB: hazard ratio [HR], 0.63; 95% CI, 0.50 to 0.79; P < .001; C v CBM: HR, 0.59; 95% CI, 0.47 to 0.75; P < .001). After a median follow-up of 31 months, median OS was 18.9 months for capecitabine and was 16.4 months for CBM; these data were not significantly different. Toxicity rates were acceptable, and all treatment regimens well tolerated. Bevacizumab toxicities were similar to those in previous studies. Measures of overall QOL were similar in all groups. Conclusion: Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL. |
Keywords: | Humans Colorectal Neoplasms Neoplasm Metastasis Hypotension Thrombocytopenia Diarrhea Mitomycin Fluorouracil Deoxycytidine Antineoplastic Combined Chemotherapy Protocols Antibodies, Monoclonal Treatment Outcome Quality of Life Adult Aged Aged, 80 and over Middle Aged Australasia Female Male Kaplan-Meier Estimate Antibodies, Monoclonal, Humanized Bevacizumab Capecitabine |
Rights: | © 2010 by American Society of Clinical Oncology |
DOI: | 10.1200/JCO.2009.27.7723 |
Published version: | http://dx.doi.org/10.1200/jco.2009.27.7723 |
Appears in Collections: | Aurora harvest 5 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.